Fig. 4: NCK synergizes with MEK inhibitors to decrease KRAS-mutant PDAC cell survival. | Cell Death & Disease

Fig. 4: NCK synergizes with MEK inhibitors to decrease KRAS-mutant PDAC cell survival.

From: Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRASG12D-mutant pancreatic ductal adenocarcinoma

Fig. 4: NCK synergizes with MEK inhibitors to decrease KRAS-mutant PDAC cell survival.

A Total cell number assay was performed to measure the survival fraction of PDAC cells after treatment with indicated concentration (log scale) of NCK and MEK inhibitors (Trametinib, Selumetinib, or Binimetinib) for 6 days. B The logarithmic combination index (CI) value of NCK and the indicated MEK inhibitors in PDAC cells was determined using the Chou-Talalay method (http://www.combosyn.com). CI value indicates: <1 synergism; =1 additive; >1 antagonism. C Dose-response curves for PDAC cells treated with the indicated concentration (log scale) of MEK inhibitors ± 5 μM NCK for 6 days using total cell number assays. The arrow indicates fold reduction in the IC50 of respective MEK inhibitors in the presence of NCK.

Back to article page